Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Neurotech International ( (AU:NTI) ) just unveiled an announcement.
Neurotech International Limited has applied for quotation on the ASX of 21,428,570 new fully paid ordinary shares, to be traded under its existing ticker NTI. The newly issued securities, linked to a previously announced transaction, expand the company’s quoted capital base and may influence liquidity and ownership structure for existing and prospective investors.
The shares are scheduled to be quoted following their issue date of March 30, 2026, subject to ASX processes and listing rules. This capital move underscores Neurotech International’s ongoing efforts to access equity markets to support its operational and strategic objectives in the neurotechnology field.
The most recent analyst rating on (AU:NTI) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Neurotech International stock, see the AU:NTI Stock Forecast page.
More about Neurotech International
Neurotech International Limited, listed on the ASX under the code NTI, operates in the broader neurotechnology and medical technology sector. The company focuses on developing and commercializing technologies and solutions related to neurological health, targeting both clinical and consumer markets seeking advanced diagnostic or therapeutic tools.
Average Trading Volume: 1,298,330
Technical Sentiment Signal: Sell
Current Market Cap: A$16.85M
For an in-depth examination of NTI stock, go to TipRanks’ Overview page.